BRIDGEBIO PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.73 USD | +2.06% |
|
-10.87% | -33.79% |
| Sep. 17 | Sector Update: Health Care Stocks Steady Premarket Tuesday | MT |
| Sep. 17 | BridgeBio Gets FDA Breakthrough Therapy Designation for Achondroplasia Treatment | DJ |
Chart calendar BridgeBio Pharma, Inc.
909e2ff.5mJToVUXXfyyT2z80dOUHkRkoVxcQ7ntGBSs3ZV0KLs.twNn9DxnFq_8Fxm1obz4bxQp1DMWJYDUfSbj5Ns5UM-TDBfnBHJryvQ8IQ~4538311ebbb2af40b2942cc871846faa
Upcoming events on BridgeBio Pharma, Inc.
Past events on BridgeBio Pharma, Inc.
| 2024-09-17 10:20 am | Cantor Global Healthcare Conference |
| 2024-09-04 | Wells Fargo Healthcare Conference |
| 2024-09-04 10:00 am | Morgan Stanley Healthcare Conference |
| 2024-08-30 10:00 am | European Society of Cardiology Congress - Dr. Mathew S. Maurer |
| 2024-08-01 07:30 am | Q2 2024 Earnings Release |
| 2024-06-21 12:00 pm | Annual General Meeting |
| 2024-06-12 03:20 pm | Goldman Sachs Global Healthcare Conference |
| 2024-06-04 08:00 am | PROPEL 2 Phase II Trial Results Call |
| 2024-05-29 05:30 pm | International Amyloidosis Symposium |
| 2024-05-29 11:30 am | International Amyloidosis Symposium - Cardiovascular Death or Hospitalization in Transthyretin Amylo |
| 2024-05-29 11:30 am | International Amyloidosis Symposium - TTR is Associated with a Lower Risk of Cardiovascular Hospital |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Acoramidis Improves Clinical Outcomes |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Health Related Quality of Life |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Higher Risk of Mortality |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Rationale & Design |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Acoramidis Significantly Improves NT-proBNP |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Acoramidis May Improve Cardiac Function |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Independent Predictor of Improved Survival in ATTR Cardiomyopa |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - ITT Sensitivity Analysis |
| 2024-05-29 11:00 am | International Amyloidosis Symposium - Improved Health Related Quality of Life |
Annual results
| Fiscal Period | December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 69,7 78,3 -10.92% | 77,6 80,3 -3.36% | 9,30 11,3 -17.31% | 367 | 220 | 519 |
|
EBITDA Million USD | Released Forecast Spread | -577 -557 -3.53% | -505 -500 -1.16% | -593 -535 -10.93% | -24,3 | -507 | -237 |
|
EBIT Million USD | Released Forecast Spread | -577 -551 -4.6% | -512 -499 -2.64% | -607 -568 -6.87% | -411 | -587 | -394 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -586 -576 -1.9% | -485 -469 -3.32% | -653 -635 -2.82% | -438 | -653 | -477 |
|
Net income Million USD | Released Forecast Spread | -563 -534 -5.42% | -481 -477 -0.79% | -643 -624 -3.05% | -419 | -604 | -429 |
|
EPS USD | Released Forecast Spread | -3,90 -3,74 -4.31% | -3,26 -3,21 -1.52% | -3,95 -3,87 -2.15% | -2,03 | -3,22 | -2,26 |
| Announcement Date | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | June | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,34 4,67 -92.76% | 1,87 5,03 -62.8% | 1,83 3,23 -43.49% | 1,64 2,99 -45.18% | 4,09 4,49 -8.8% | 1,75 3,79 -53.96% | 211 83,8 152% | 2,17 4,48 -51.55% | 3,55 | 154 | 27,3 | 46,7 | 58,5 | 60,7 |
|
EBITDA Million USD | Released Forecast Spread | -124 -146 15% | -129 -116 -11.03% | -125 -132 5.62% | -141 -133 -5.61% | -156 -140 -11.47% | -175 -145 -20.71% | 27,8 -143 119.49% | -171 -141 -20.92% | -148 | 283 | ||||
|
EBIT Million USD | Released Forecast Spread | -124 -139 10.73% | -129 -116 -11.36% | -126 -119 -5.95% | -146 -122 -19.5% | -158 -127 -23.71% | -177 -144 -22.84% | 0,34 -117 100.29% | -176 -187 6.18% | -179 | -84,9 | -165 | -141 | -141 | -151 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -140 -154 8.68% | -141 -125 -12.52% | -143 -132 -8.06% | -161 -134 -19.57% | -179 -142 -26.83% | -170 -165 -3.07% | -36,2 -99,7 63.75% | -75,5 -209 63.94% | -197 | -193 | -191 | -164 | -160 | -170 |
|
Net income Million USD | Released Forecast Spread | -137 -143 4.08% | -138 -128 -7.62% | -140 -126 -10.86% | -158 -129 -22.65% | -177 -133 -32.9% | -168 -158 -6.25% | -35,2 -122 71.14% | -73,5 -192 61.77% | -194 | -197 | -191 | -163 | -157 | -169 |
|
EPS USD | Released Forecast Spread | -0,93 -0,99 5.89% | -0,92 -0,85 -8.18% | -0,92 -0,83 -10.92% | -0,98 -0,83 -17.69% | -1,08 -0,81 -32.63% | -0,96 -0,92 -4.25% | -0,20 -0,51 60.72% | -0,39 -1,06 63.08% | -0,97 | -0,54 | -0,95 | -0,85 | -0,84 | -0,84 |
| Announcement Date | 03/11/22 | 23/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 22/02/24 | 02/05/24 | 01/08/24 | - | - | - | - | - | - |
More events
Past sector events for BridgeBio Pharma, Inc.
| 2024-09-09 04:05 pm | AVID BIOSERVICES, INC.: Q1 2025 Earnings Release |
| 2024-09-05 06:30 am | KALVISTA PHARMACEUTICALS, INC.: Q1 2025 Earnings Release |
| 2024-08-30 11:56 pm | SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: Q2 2024 Earnings Release |
| 2024-08-30 | TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: Q2 2024 Earnings Release |
| 2024-08-29 | CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.: Q2 2024 Earnings Release |
| 2024-08-29 | BEIJING BOHUI INNOVATION BIOTECHNOLOGY GROUP CO., LTD.: Q2 2024 Earnings Release |
| 2024-08-29 | HUALAN BIOLOGICAL VACCINE INC.: Q2 2024 Earnings Release |
| 2024-08-29 | HUALAN BIOLOGICAL ENGINEERING INC.: Q2 2024 Earnings Release |
| 2024-08-29 07:32 am | CLINUVEL PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
| 2024-08-28 | AIM VACCINE CO., LTD.: Q2 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- BBIO Stock
- Calendar BridgeBio Pharma, Inc.